• Wondering whether Vera Therapeutics at around US$40.45 is still offering value, or if the easy gains are behind it? This article is designed to help you frame that question clearly.
• The stock has returned 6.2% over the last week and 3.5% over the last month, while year to date it is down 16.8% but up 102.8% over the past year and a very large amount over three years. This naturally raises questions about what is already priced in.
• Recent coverage has focused on Vera Therapeutics as investors reassess high growth biotech names, highlighting how sharply the share price has moved over the last year and how sentiment toward smaller drug developers can change quickly. That context matters if you are trying to decide whether current expectations around the business are too optimistic, too cautious, or somewhere in between.
• Right now, Vera Therapeutics has a valuation score of 3 out of 6. The stock appears undervalued on half of the checks and less compelling on the other half, and the sections that follow will walk through the main valuation approaches while hinting at an even richer way to think about fair value at the end.

Approach 1: Vera Therapeutics Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today to estimate what the business might be worth right now. It is essentially a way of translating tomorrow’s expected cash into today’s dollars.

For Vera Therapeutics, the latest twelve month free cash flow is a loss of $241.7 million. Analysts provide explicit estimates out to 2030, with Simply Wall St extrapolating further. Within those projections, free cash flow is expected to reach $704.8 million in 2030. According to the model’s ten year forecast path, the interim years move from losses into positive territory.

Using a 2 Stage Free Cash Flow to Equity model, these projected cash flows are discounted back to today and result in an estimated intrinsic value of about $436.72 per share. Against a recent share price of roughly $40.45, the DCF output implies the stock is 90.7% undervalued based on these inputs and assumptions.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Vera Therapeutics is undervalued by 90.7%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Vera Therapeutics Price vs Book

For companies that are not yet generating consistent profits or sales, the price to book, or P/B, ratio is often a practical yardstick because it compares what you pay per share to the accounting value of the net assets backing that share. It is especially common for early stage or biotech names where earnings and revenue can be volatile or negative.

In general, higher expected growth and lower perceived risk can support a higher P/B multiple. Slower growth and higher risk usually point to a lower “normal” or “fair” range. That is why simple comparisons can be misleading if they ignore differences in balance sheet strength or business profile.

Vera Therapeutics currently trades on a P/B of 4.77x. The broader Biotechs industry average P/B is about 2.22x, while the peer group referenced here sits higher at roughly 6.47x. Simply Wall St’s proprietary “Fair Ratio” aims to refine this comparison by estimating the P/B that might make sense given factors such as earnings growth, profit margins, market cap, risk profile and industry.

Because the Fair Ratio is not available here, it is not possible to say whether the present 4.77x is clearly cheap, expensive or roughly in line with those fundamentals.

Result: ABOUT RIGHT

P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose Your Vera Therapeutics Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Think of Narratives as your way to attach a clear story about Vera Therapeutics to the numbers you are seeing, including your own assumptions for fair value, future revenue, earnings and margins.

A Narrative connects three pieces in a simple chain: what you believe about the business, how that belief flows into a financial forecast, and the fair value that comes from those estimates.

On Simply Wall St, Narratives sit inside the Community page and are designed to be quick to set up, easy to compare, and accessible for investors who want more structure without building a full model themselves.

They help you decide whether to act by lining up your fair value against the current share price, then updating that picture as new information such as earnings releases or news arrives.

For Vera Therapeutics, one investor might see a very conservative path with modest revenue growth and cautious margins, while another might expect stronger adoption and higher profitability. This can lead each of them to very different fair values and very different views on whether the current price around US$40.45 feels attractive or not.

Do you think there's more to the story for Vera Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.